Physician profile
Ellen Tindal
NPI 1003120700
$2,249.00
in general payments reported to CMS, 2019-2025
10 companies · $1,772 in 2025
The $1,772 reported for 2025 was more than what 98% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.87 · 2023: $225 · 2024: $218 · 2025: $1,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,338 · Travel and Lodging: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,338.01 |
| Travel and Lodging | $877.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $1,199.91 | 2025 | |
| Coloplast Corp | $463.48 | 2023-2025 | Peristeen, Speedicath |
| Abbvie INC. | $171.48 | 2023-2025 | |
| Alcresta Therapeutics, INC. | $120.68 | 2025 | Relizorb |
| Regeneron Healthcare Solutions, INC. | $120.18 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $50.62 | 2023-2024 | Gattex |
| Genzyme Corporation | $48.22 | 2022-2025 | |
| Soleno Therapeutics, INC. | $34.35 | 2025 | Vykat Xr |
| Janssen Biotech, INC. | $20.55 | 2025 | Tremfya |
| Regeneron Pharmaceuticals, INC. | $19.53 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Tindal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.